Allergan paid CEO Brent Saunders $32.8M for 2017 — 3 insights

Allergan CEO Brent Saunders received $32.8 million as the drugmaker's shares fell, Bloomberg reports.

Here's what you should know.

1. Mr. Saunders was awarded $22.7 million in restricted stock. Approximately 75 percent of it will only vest if the company meets goals related to shareholder returns as well as research and development.

2. Mr. Saunders also received $8.75 million in cash bonuses, boosting his base salary by $1.3 million.

3. In 2017, Allergan's shares decreased in value by 22 percent, while the rest of the S&P 500 Health Care Index increased 20 percent.

More articles on supply chain:
Nobilis looking for more large in-network acquisitions in 2018: 5 key quotes from CEO Harry Fleming
Congress questions Joint Commission accreditation process — 7 insights
Common deficiencies cited by AAAASF and how to fix them: Administration of drugs

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Featured Webinars

Featured Whitepapers